Investigational Drug Information for BMS-963272
What is the development status for investigational drug BMS-963272?
BMS-963272 is an investigational drug.
There have been 4 clinical trials for BMS-963272.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2019.
The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Obesity. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].
There are eleven US patents protecting this investigational drug and sixty-seven international patents.
Summary for BMS-963272
| US Patents | 11 |
| International Patents | 67 |
| US Patent Applications | 21 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2019-09-30) |
| Vendors | 17 |
Recent Clinical Trials for BMS-963272
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease | Bristol-Myers Squibb | Phase 1 |
| A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin | Bristol-Myers Squibb | Phase 1 |
| A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults | Bristol-Myers Squibb | Phase 1 |
Clinical Trial Summary for BMS-963272
Top disease conditions for BMS-963272
Top clinical trial sponsors for BMS-963272
US Patents for BMS-963272
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BMS-963272 | ⤷ Start Trial | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| BMS-963272 | ⤷ Start Trial | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| BMS-963272 | ⤷ Start Trial | Bridged bicyclic compounds as farnesoid X receptor modulators | Bristol Myers Squibb Co | ⤷ Start Trial |
| BMS-963272 | ⤷ Start Trial | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| BMS-963272 | ⤷ Start Trial | Substituted amide compounds useful as farnesoid X receptor modulators | Bristol Myers Squibb Co | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BMS-963272
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BMS-963272 | Argentina | AR090041 | 2031-12-02 | ⤷ Start Trial |
| BMS-963272 | Australia | AU2012345863 | 2031-12-02 | ⤷ Start Trial |
| BMS-963272 | Brazil | BR112014013228 | 2031-12-02 | ⤷ Start Trial |
| BMS-963272 | Canada | CA2857689 | 2031-12-02 | ⤷ Start Trial |
| BMS-963272 | Chile | CL2014001437 | 2031-12-02 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
